{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-013592","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.887241+00:00","generated_at":"2026-06-15T07:41:44.864758+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioCardia Q1 2023 net loss $3.5M; adaptive FDA plan for heart failure trial submitted","bullets":["Revenue $64K (flat YoY); net loss $3.5M vs $3.3M; cash used in ops $2.6M.","Phase III CardiAMP HF trial: adaptive statistical analysis plan submitted to FDA Apr 26; DSMB meeting late June.","Japan PMDA submission expected Q2 2023 for CardiAMP; roll-in cohort 2-yr survival 100%.","BCDA-03 allogeneic HFrEF trial first patient expected Q2 2023; BCDA-04 ARDS trial start Q4 2023.","FDA audit of quality system resulted in zero written observations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-013592","json":"https://secwatch.observer/filing/0001437749-23-013592.json","markdown":"https://secwatch.observer/filing/0001437749-23-013592.md","text":"https://secwatch.observer/filing/0001437749-23-013592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774923013592/0001437749-23-013592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774923013592/bcda20230510_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:41:44.864758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ffec85ce95996bcdadcf9db28685e05acd334a71","claim":"BioCardia, Inc. reported first quarter of 2023 results: revenue approximately $64 thousand.","evidence_excerpt":"CellProthera’s next clinical study, and potential early access commercialization, which could begin in 2024. First Quarter 2023 Financial Results: > Revenues were approximately $64 thousand for the three months ended March 2023, compared for approximately $60 thousand in the three months ended March 2022. > Research and development expenses increased to a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774923013592/0001437749-23-013592-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"approximately $64 thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}